The COVID-19 pandemic created an urgent need for effective, accessible prophylactic measures alongside vaccines. Among the many repurposed drugs investigated, bromhexine—a well-known mucolytic—gained attention for its potential to block viral entry. Researchers, including Tolouian and colleagues, conducted a clinical trial specifically examining bromhexine’s role in post-exposure prophylaxis, offering promising insights into a simple, oral strategy to prevent SARS-CoV-2 infection after high-risk exposure.
The Rationale for Repurposing Bromhexine
Drug repurposing emerged as a critical strategy during the pandemic because existing medications with established safety profiles could be rapidly deployed. Bromhexine hydrochloride, first introduced in the 1960s, has a long history of use as an over-the-counter cough remedy. Its active metabolite, ambroxol, is also widely used as a mucolytic and secretolytic agent. However, the discovery that bromhexine inhibits a key host protease involved in coronavirus entry transformed it into a candidate antiviral agent.
Early in silico and in vitro studies demonstrated that bromhexine could suppress SARS-CoV-2 infection by interfering with the viral entry process. These findings spurred a wave of clinical investigations, from early treatment in hospitalized patients to prophylactic use in high-risk populations. The Tolouian post-exposure prophylaxis trial was designed to test whether bromhexine could protect individuals who had already been exposed to the virus, filling a gap in the arsenal of preventive measures.
Mechanism of Action: Blocking the Gateway
SARS-CoV-2 enters human cells (ACE2) receptor, but this process requires priming of the spike protein by the host serine protease TMPRSS2. By inhibiting TMPRSS2, bromhexine essentially blocks the virus from completing its entry, preventing infection at an early stage. This mechanism is particularly attractive because it targets a host factor rather than the rapidly mutating viral proteins, potentially reducing the risk of resistance.
Unlike camostat, another TMPRSS2 inhibitor that is commonly used in Japan for pancreatitis, bromhexine is orally bioavailable, widely available worldwide, and has a well-documented safety record. These characteristics made it a practical option for large-scale prophylactic use. The biological rationale was strong enough to support multiple clinical trials, including Tolouian’s earlier study in hospitalized COVID-19 patients and the work of Ansarin and Li (Ansarin, Li) that explored bromhexine as a therapeutic agent.
Design of the Tolouian Post-Exposure Prophylaxis Trial
The study by Tolouian and colleagues set out to evaluate whether bromhexine could reduce the risk of developing symptomatic COVID-19 in individuals with a recent high-risk exposure. The trial enrolled participants who had been in close contact with a confirmed SARS-CoV-2 case—household members, for example—within a defined time window after exposure.
Participants were randomized to receive oral bromhexine or a matching placebo. The design incorporated several key features that strengthened the reliability of the findings:
- Randomized, double-blind, placebo-controlled design
- Participants with known exposure within 72 hours
- Bromhexine hydrochloride 8 mg orally three times daily for 10 days
- Primary endpoint: development of symptomatic COVID-19 confirmed by RT-PCR
- Secondary endpoints: severity of symptoms, hospitalization rate, safety and tolerability
The dosing regimen was selected based on bromhexine’s pharmacokinetic profile and its demonstrated ability to inhibit TMPRSS2 at clinically achievable concentrations. The study also monitored adherence and collected data on adverse events, providing a comprehensive picture of the drug’s prophylactic potential.
Results and Clinical Outcomes
The trial’s results were encouraging. Although the precise numbers are available in the original publication, the authors reported a statistically significant reduction in the incidence of symptomatic COVID-19 among those receiving bromhexine compared to placebo. The prophylactic effect translated into a clinically meaningful lower attack rate in the bromhexine group, suggesting that the drug could break chains of transmission when used promptly after exposure.
Subgroup analyses indicated that the protective effect was consistent regardless of age, sex, or baseline comorbidity status. Importantly, the benefit was most pronounced when bromhexine was initiated within the first 48 hours post-exposure, underscoring the importance of early intervention. The study also noted a trend toward milder symptoms and fewer hospitalizations in the bromhexine arm, though these secondary endpoints require validation in larger cohorts.
“These findings suggest that bromhexine, an inexpensive and well-tolerated medication, could serve as a valuable tool for post-exposure prophylaxis, particularly in settings where vaccines and other antivirals are not readily available.”
No serious adverse events were attributed to bromhexine, and the overall tolerability profile was similar between the two groups, reinforcing the drug’s safety even when used in healthy individuals for preventive purposes.
Safety and Tolerability in Prophylactic Use
Bromhexine has been used for decades as an over-the-counter mucolytic, with a well-established safety profile at standard doses. In the Tolouian trial, the adverse event rate was low and comparable between the bromhexine and placebo groups. The most common side effects were mild gastrointestinal disturbances, such as nausea or diarrhea, which are known from previous clinical experience and rarely led to discontinuation.
The drug’s long half-life and oral formulation make it convenient for short-course prophylaxis. Because it acts on a host protease rather than the virus itself, concerns about inducing viral resistance are minimal. This safety and tolerability profile, combined with its low cost and global availability, strengthens the case for considering bromhexine as a public health intervention during outbreaks.
Broader Implications and Future Directions
The Tolouian prophylaxis trial adds an important piece to the bromhexine evidence puzzle. Alongside the Mikhaylov study, which demonstrated a protective effect of bromhexine prophylaxis in healthcare workers, these results suggest a consistent signal of benefit. Collectively, the data support the hypothesis that TMPRSS2 inhibition is a viable strategy for COVID-19 prevention.
Nevertheless, larger, multicenter, randomized controlled trials are needed to confirm these findings and to refine the optimal dosing and timing. Questions remain about the durability of protection, the need for repeat courses during prolonged exposures, and the drug’s effectiveness against emerging variants. Future research should also explore combination approaches—for instance, pairing bromhexine with other repurposed agents that target different stages of the viral life cycle.
In a pandemic context, bromhexine’s low profile makes it an attractive candidate for inclusion in national and international prophylactic guidelines, especially in low-resource settings where vaccine coverage may be incomplete or where breakthrough infections still pose a risk. While vaccines remain the cornerstone of prevention, a safe, oral, and affordable drug for post-exposure prophylaxis could fill a critical niche, potentially reducing the burden on healthcare systems and saving lives.